
Magdalena Marczyńska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/350198/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respiratory Medicine,the, 2014, 2, 395-404.	5.2	527
2	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
3	Exposure to Antiretroviral Therapy in Utero or Early Life: the Health of Uninfected Children Born to HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 380-387.	0.9	233
4	PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIVâ€1 infection. HIV Medicine, 2009, 10, 591-613.	1.0	135
5	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	3.9	98
6	Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. Aids, 2005, 19, 1071-1079.	1.0	74
7	Mode of delivery in HIVâ€infected pregnant women and prevention of motherâ€toâ€child transmission: changing practices in Western Europe. HIV Medicine, 2010, 11, 368-378.	1.0	73
8	Use of Zidovudine-Sparing HAART in Pregnant HIV-Infected Women in Europe: 2000–2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 326-333.	0.9	71
9	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09â€related pneumonia: an individual participant data metaâ€analysis. Influenza and Other Respiratory Viruses, 2016, 10, 192-204.	1.5	54
10	Body Fat Abnormality in HIV-Infected Children and Adolescents Living in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 314-324.	0.9	51
11	Guidance on vaccination of <scp>HIV</scp> â€infected children in <scp>E</scp> urope. HIV Medicine, 2012, 13, 333-336.	1.0	47
12	Age-Related Standards for Total Lymphocyte, CD4+ and CD8+ T Cell Counts in Children Born in Europe. Pediatric Infectious Disease Journal, 2005, 24, 595-600.	1.1	42
13	Response to planned treatment interruptions in HIV infection varies across childhood. Aids, 2010, 24, 231-241.	1.0	38
14	Environmental and personal risk factors for toxocariasis in children with diagnosed disease in urban and rural areas of central Poland. Veterinary Parasitology, 2008, 155, 217-222.	0.7	37
15	Is liver biopsy still needed in children with chronic viral hepatitis?. World Journal of Gastroenterology, 2015, 21, 12141.	1.4	34
16	Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. PLoS Medicine, 2018, 15, e1002491.	3.9	29
17	The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. PLoS ONE, 2013, 8, e76582.	1.1	29
18	Increasing likelihood of further live births in HIV-infected women in recent years. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 881-888.	1.1	26

#	Article	IF	CITATIONS
19	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antiviral Therapy, 2010, 15, 297-305.	0.6	26
20	Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation. Clinical Infectious Diseases, 2012, 54, 878-881.	2.9	26
21	Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. Aids, 2013, 27, 579-589.	1.0	24
22	Insufficient Antiretroviral Therapy in Pregnancy: Missed Opportunities for Prevention of Mother-To-Child Transmission of HIV in Europe. Antiviral Therapy, 2011, 16, 895-903.	0.6	22
23	Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV,the, 2019, 6, e105-e115.	2.1	22
24	Prevalence and predictors of liver disease in HIV-infected children and adolescents. Scientific Reports, 2017, 7, 12309.	1.6	21
25	Comparison of clinical severity and epidemiological spectrum between coronavirus disease 2019 and influenza in children. Scientific Reports, 2021, 11, 5760.	1.6	21
26	A serological and epidemiological evaluation of risk factors for toxocariasis in children in central Poland. Journal of Helminthology, 2008, 82, 123-127.	0.4	20
27	Euroguidelines in Central and Eastern Europe (<scp>ECEE</scp>) conference and the Warsaw Declaration – a comprehensive meeting report. HIV Medicine, 2017, 18, 370-375.	1.0	19
28	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverseâ€Transcriptase Inhibitors in HIV Type 1–Infected Children. Clinical Infectious Diseases, 2008, 46, 1601-1608.	2.9	16
29	Pneumonia, gastrointestinal symptoms, comorbidities, and coinfections as factors related to a lengthier hospital stay in children with COVID-19—analysis of a paediatric part of Polish register SARSTer. Infectious Diseases, 2022, 54, 196-204.	1.4	16
30	Clinical and Epidemiological Characteristics of 1283 Pediatric Patients with Coronavirus Disease 2019 during the First and Second Waves of the Pandemic—Results of the Pediatric Part of a Multicenter Polish Register SARSTer. Journal of Clinical Medicine, 2021, 10, 5098.	1.0	16
31	Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008. Journal of Medical Virology, 2010, 82, 1291-1294.	2.5	14
32	Risk of human toxocarosis in Poland due to Toxocara infection of dogs and cats. Acta Parasitologica, 2014, 60, 99-104.	0.4	13
33	COVID-19 infections in infants. Scientific Reports, 2022, 12, 7765.	1.6	13
34	The influence of hepatitis B and C virus coinfection on liver histopathology in children. European Journal of Pediatrics, 2015, 174, 345-353.	1.3	12
35	Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand. Clinical Infectious Diseases, 2018, 66, 594-603.	2.9	12
36	Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. BMC Infectious Diseases, 2017, 17, 361.	1.3	11

#	Article	IF	CITATIONS
37	Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. Aids, 2017, 31, 127-135.	1.0	10
38	Liver steatosis in children with chronic hepatitis B and C. Medicine (United States), 2017, 96, e5832.	0.4	10
39	HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 42-53.	0.9	9
40	Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption. Aids, 2016, 30, 1075-1081.	1.0	9
41	Determinants of liver disease progression in children with chronic hepatitis C virus infection. Polish Journal of Pathology, 2015, 4, 368-375.	0.1	8
42	Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. Clinical Infectious Diseases, 2019, 70, 404-415.	2.9	8
43	Liver Fibrosis Evaluated With Transient Elastography in 35 Children With Chronic Hepatitis C Virus Infection. Pediatric Infectious Disease Journal, 2021, 40, 103-108.	1.1	8
44	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. Journal of the International AIDS Society, 2022, 25, e25871.	1.2	8
45	Vertical Transmission of HIV-1 in Poland. Scandinavian Journal of Infectious Diseases, 2000, 32, 165-167.	1.5	7
46	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. BMC Infectious Diseases, 2016, 16, 654.	1.3	7
47	Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. European Journal of Clinical Pharmacology, 2017, 73, 463-468.	0.8	7
48	Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project. Journal of Clinical Medicine, 2021, 10, 4176.	1.0	7
49	Hepatitis C infection among pregnant women in central Poland: Significance of epidemiological anamnesis and impact of screening tests to detect infection. Advances in Clinical and Experimental Medicine, 2019, 28, 313-318.	0.6	7
50	Levels and patterns of HIV RNA viral load in untreated pregnant women. International Journal of Infectious Diseases, 2009, 13, 266-273.	1.5	6
51	Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS and Behavior, 2013, 17, 193-202.	1.4	6
52	Safety of Darunavir and Atazanavir in HIV-Infected Children in Europe and Thailand. Antiviral Therapy, 2016, 21, 353-358.	0.6	6
53	Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections. Journal of Infection and Chemotherapy, 2016, 22, 65-71.	0.8	6
54	Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest – comparison with histopathological assessment. Clinical and Experimental Hepatology, 2017, 4, 187-193.	0.6	6

#	Article	IF	CITATIONS
55	Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C. Clinical and Experimental Hepatology, 2017, 4, 198-202.	0.6	6
56	Cardiovascular diseases associated with HIV infection and their management. Kardiologia Polska, 2013, 71, 1183-1187.	0.3	6
57	Outcomes of secondâ€line antiretroviral therapy among children living with HIV: a global cohort analysis. Journal of the International AIDS Society, 2020, 23, e25477.	1.2	5
58	Occurrence of Clostridium difficile in fecal samples of HIV-infected children in Poland. Anaerobe, 2003, 9, 295-297.	1.0	4
59	One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis—A Case Series Report. Viruses, 2021, 13, 1518.	1.5	4
60	Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious Diseases. Przeglad Epidemiologiczny, 2016, 70, 297-310.	0.4	4
61	The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C. Viruses, 2022, 14, 474.	1.5	4
62	Cowpox Virus Infection. New England Journal of Medicine, 2018, 378, 181-181.	13.9	3
63	Both improvement and worsening of adherence to antiretroviral treatment can be expected while transitioning HIV-positive adolescents to adult health care. Infectious Diseases, 2019, 51, 463-466.	1.4	3
64	Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report. Pediatric Infectious Disease Journal, 2021, 40, 1087-1089.	1.1	3
65	Recommended management of Toxoplasma gondii infection in pregnant women and their children. Przeglad Epidemiologiczny, 2015, 69, 291-8, 403-10.	0.4	3
66	Rekomendacje zespoÅ,u ekspertów dotyczÄce stosowania dwudawkowego schematu szczepieÅ" przeciw ospie wietrznej. Pediatria Polska, 2010, 85, 243-250.	0.1	2
67	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. Vaccine, 2016, 34, 5587-5594.	1.7	2
68	Children living with HIV in Europe: do migrants have worse treatment outcomes?. HIV Medicine, 2022, 23, 186-196.	1.0	2
69	Predictors of Liver Disease Severity in Children with Chronic Hepatitis B. Advances in Clinical and Experimental Medicine, 2016, 25, 681-688.	0.6	2
70	Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klinische Padiatrie, 2021, 233, 211-215.	0.2	2
71	Meningitis and Ramsay-Hunt syndrome in a 17-year old girl. Neuroendocrinology Letters, 2019, 40, 149-151.	0.2	2
72	Genetic detection of HLA-B*5701 allele for prediction of Abacavir hypersensitivity among HIV-positive patients in Polish population. HIV and AIDS Review, 2009, 8, 13-16.	0.1	1

#	Article	IF	CITATIONS
73	Pandemic A (H1N1) Influenza in Hospitalized Children in Warsaw, Poland. Pediatric Infectious Disease Journal, 2011, 30, 90.	1.1	1
74	Zalecenia terapeutyczne dla dzieci zakażonych HIV. HIV and AIDS Review, 2013, 12, 116-118.	0.1	1
75	Health-related quality of life in Polish children and adolescents with perinatal HIV infection – short report. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1393-1399.	0.6	1
76	Reply to letter by Zuccotti et al Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 487-487.	0.7	1
77	Reply to letter by Zuccotti et al Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 487-487.	0.7	0
78	A suspicion of aspergillosis in a child with AIDS – a case report. HIV and AIDS Review, 2009, 8, 20-22.	0.1	0
79	1453 Factors Influencing Long-Term Immunity Against Hepatitis B - the Role of Natural Boosters. Pediatric Research, 2010, 68, 718-718.	1.1	0
80	Candidiasis in a 3-month-old vertically HIV-infected infant. HIV and AIDS Review, 2010, 9, 14-16.	0.1	0
81	Antibody response to VZV vaccination in HIV infected children. HIV and AIDS Review, 2015, 14, 76-79.	0.1	0
82	A 12-Year-Old Returning Traveler with Fever, Retro-orbital Headache and Rash. Klinische Padiatrie, 2017, 229, 100-101.	0.2	0
83	Zaburzenia neurologiczne u dzieci wertykalnie zakażonych HIV. Pediatria Polska, 2017, 92, 561-566.	0.1	0
84	Pruritic, Bizarre Tracks- A Vacation Souvenir. Klinische Padiatrie, 2018, 230, 102-103.	0.2	0
85	A current HCV infection may increase the risk of preterm birth among HIV-positive women. Sexually Transmitted Infections, 2020, 96, 335-336.	0.8	0
86	The micro-elimination approach - a new way of tackling hepatitis C in paediatric population. Archives of Medical Science, 2021, , .	0.4	0
87	Non-Vertical Exposures to HIV, HBV and HCV Infection in Children and Adolescents—Risk of Infection, Standards of Care and Postexposure Prophylaxis. Pediatric Reports, 2021, 13, 566-575.	0.5	0
88	On a straight path to HCV elimination in children – new prospects for hepatitis C treatment in Poland. Przeglad Epidemiologiczny, 2020, 74, 662-666.	0.4	0
89	Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals. Minerva Pediatrics, 2021, , .	0.2	0